Risk factors
Matinas BioPharma Holdings (MTNB) risk factors
Item 1A of every Matinas BioPharma Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks3 new2 dropped5 reworded
Matinas BioPharma faces severe dilution, listing compliance challenges, and extreme staffing constraints with only two full-time employees.
Filed Mar 31, 2026 - FY2024 10-K risk factors54 risks
Matinas BioPharma faces severe going concern doubts following the paused development of its lead product, MAT2203, and terminated partner negotiations. The company operates with a skeleton crew of three employees, an accumulated deficit of $199.8 million, and a net loss of $24.3 million in 2024. Survival depends entirely on finding strategic alternatives, raising additional capital, or executing a corporate winddown.
Filed Apr 15, 2025